Shots:
- Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, incl. its Hypercon technology, which enables biologic formulations at concentrations of 400-500mg/ml
- As per the deal, Elektrofi will receive $750M upfront, with up to three $50M milestone payments contingent on regulatory approvals of three separate Hypercon products; closing expected in Q4’25
- As a result of the acquisition, Halozyme may earn ~$275M in development & commercial milestones from Elektrofi’s existing 2 partnered products, anticipated to enter clinical trials by end-2026 or earlier, with royalty revenues expected from 2030
Ref: Halozyme Therapeutics | Image: Elektrofi| Press Release
Related News:- Genmab to Acquire Merus for ~$8B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
